CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 65 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Everolimus 5 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01734512
NCT01734512Phase 2Completed
CompareCT.gov

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

University of California, San Francisco·interventional·Posted Nov 27, 2012·Updated Sep 9, 2025

In Brief

A Phase 2 clinical trial evaluating Everolimus for Pediatric Recurrent Progressive Low-grade Gliomas and Pediatric Progressive Low-grade Gliomas. Completed, enrolled 65 participants across 18 sites.

Detailed Summary

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium, The Pediatric Low Grade Astrocytoma (PLGA) Foundation

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 27, 2012
Enrollment StartDec 13, 2012
Primary CompletionJan 31, 2020
Study CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 13.6 years ago

Interventions

Everolimusdrug

Everolimus tablet will be taken daily by mouth with water. All participants will be given a dose of 5 mg/m2/dose daily.